Human tissue derived compositions and uses thereof

US12310993B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12310993-B2
Application numberUS-201816229823-A
CountryUS
Kind codeB2
Filing dateDec 21, 2018
Priority dateJun 24, 2016
Publication dateMay 27, 2025
Grant dateMay 27, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed are compositions comprising a non-homogenized chorionic matrix, a homogenized amniotic matrix and a homogenized UC (UC) matrix, wherein the non-homogenized chorionic matrix comprises viable cells. Disclosed are methods of making the compositions disclosed herein comprising preparing a non-homogenized chorionic matrix, preparing a homogenized amniotic matrix, preparing a homogenized UC matrix, and combining the non-homogenized chorionic matrix, the non-homogenized chorionic matrix, and the homogenized UC matrix. Disclosed are methods of treating a tissue injury or chronic pain comprising administering any of the disclosed compositions to an area of a subject comprising a tissue injury.

First claim

Opening claim text (preview).

We claim: 1. A composition comprising a minced chorionic matrix and a devitalized homogenized umbilical cord (UC) matrix, wherein the minced chorionic matrix comprises native cells, wherein the composition does not comprise trophoblasts or an amniotic matrix, wherein the composition is lyophilized, wherein at least 70% of the native cells of the minced chorionic matrix are viable after storage at room temperature in the lyophilized state, wherein the minced chorionic matrix and the devitalized homogenized UC matrix are each in particulate form, wherein the minced chorionic matrix has a larger average particle size than the devitalized homogenized UC matrix, and wherein the devitalized homogenized UC matrix does not include Wharton's jelly. 2. The composition of claim 1 , wherein the composition is formulated as a cream, gel, oil, ointment, or lotion. 3. The composition of claim 1 further comprising viable, isolated amniotic cells. 4. The composition of claim 1 , wherein the homogenized UC matrix is not decellularized. 5. The composition of claim 1 , wherein the minced chorionic matrix is not homogenized. 6. The composition of claim 1 , wherein the composition comprises viable chorionic stem cells, amniotic stem cells, fibroblasts, epithelial cells or a combination thereof. 7. The composition of claim 1 , wherein the minced chorionic matrix and homogenized UC matrix are from the same donor. 8. The composition of claim 1 , wherein the homogenized UC matrix comprises de-veined UC tissue. 9. The composition of claim 1 , wherein the minced chorionic matrix comprises greater than or equal to 100,000 viable cells/ml. 10. The composition of claim 1 , wherein at least 75% of the native cells of the minced chorionic matrix are viable after storage at room temperature in the lyophilized state. 11. The composition of claim 1 , wherein the composition further comprises a pharmaceutically acceptable excipient. 12. The composition of claim 1 , wherein the homogenized UC matrix is 10 nm to 1 mm in size. 13. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

Assignees

Inventors

Classifications

  • Umbilical cord; Umbilical cord blood; Umbilical stem cells · CPC title

  • Ingredients of undetermined constitution or reaction products thereof · CPC title

  • Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells · CPC title

  • characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel · CPC title

  • for joint disorders, e.g. arthritis, arthrosis · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12310993B2 cover?
Disclosed are compositions comprising a non-homogenized chorionic matrix, a homogenized amniotic matrix and a homogenized UC (UC) matrix, wherein the non-homogenized chorionic matrix comprises viable cells. Disclosed are methods of making the compositions disclosed herein comprising preparing a non-homogenized chorionic matrix, preparing a homogenized amniotic matrix, preparing a homogenized UC…
Who is the assignee on this patent?
Osiris Therapeutics Inc
What technology area does this patent fall under?
Primary CPC classification A61K35/50. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).